Background Colorectal cancers (CRCs) expressing programmed death ligand 1 (PD-L1)
have poor prognosis. In the multicohort KEYNOTE-028 trial, the anti–PD-1 antibody
pembrolizumab was evaluated in 20 PD-L1–positive advanced solid tumors. Herein, we
report results for the advanced CRC cohort. Methods Patients with advanced, treatment-
resistant PD-L1–positive carcinoma of the colon or rectum were enrolled, regardless of
microsatellite instability (MSI) status. Pembrolizumab 10 mg/kg was administered every 2 …

Background Safety and efficacy of pembrolizumab, a humanized programmed death 1
monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for
patients with programmed death ligand 1 (PD-L1)-positive advanced solid tumors. We report
results for the cohort of patients with advanced anal carcinoma. Patients and methods
Patients with PD-L1-positive tumors (≥ 1%) received intravenous pembrolizumab 10 mg/kg
once every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity …

Background Treatment options for advanced thyroid cancer refractory to standard therapies
are limited. The safety and efficacy of pembrolizumab were evaluated in patients with
advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1).
Methods Patients with advanced thyroid cancer were enrolled in the nonrandomized, phase
Ib KEYNOTE-028 trial conducted to evaluate safety and antitumor activity of the anti–
programmed death 1 (PD-1) antibody pembrolizumab in advanced solid tumors. Key …